NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Again, I didn't say he WON"T EVER, just that the speculation about what his motives are, and what he will and won't do and why that is... is mostly ill informed and speculative, and in some posts, based upon grossly inaccurate assumptions that no doubt can be cleaned up on subsequent posts and redirected.

I agree most of the speculations about Woodford are speculative. What else would they be?!

The fact is, he has been and remains a big player in the NWBO story.
Why shouldn't members speculate about him and what his next move might be?
I expect he does know the reason for the screening hold, yet does not consider it material information in either direction.

His latest stated position on NWBO is that he continues to believe in the science and the potential, but that he is also waiting for the findings of the investigation.

We were pleased that the Northwest board appointed an independent committee to investigate the unsubstantiated claims made in the anonymous so-called research reports. We await the product of that investigation. That aside, we continue to believe in the science behind the DCVax dendritic-cell approach and its long-term potential.
Neil Woodford. 14 Mar 2016

As we said late last year, if the company is going to move into a sustainable position to attract a broader range of investors, that, in turn will give it a runway to complete its clinical trials, it needed to put allegations of financial improprieties and regulatory failure to rest once and for all.
Accordingly, we engaged with the board on this matter and in a public filing to the US Securities and Exchange Commission in November, we called for the appointment of an independent non-executive director and the convening of a special committee to investigate the allegations. The the company has initiated an investigation, which it suggested would take several months to complete and we are now awaiting its findings. As Neil said yesterday in the live Q&A we continue to believe in the science behind the DCVax dendritic-cell approach and its long-term potential.
Paul Farrow (Woodford spokesperson.) 15 Mar 2016

Even AF got in on the act by posting a question on Woodfords Q and A:-

AF:
Neil — Can you discuss NWBO in more detail? Obviously, there were a lot of cancer immunotherapy stocks you could have chosen to include in the portfolio, so why did you invest in NWBO? Have you come to doubt your investment thesis in NWBO given recent problems at the company?

And Paul Farrow replied with a straight bat:
Hi Adam,
As we have said previously, we were attracted to Northwest by its technology that looks to harness the power of the body’s immune system to fight cancer. As Neil replied yesterday during the live Q&A, we continue to believe in the science behind the DCVax dendritic-cell approach and its long-term potential.

Other than more recent statements to the effect that they are not subject to any regulation that would preclude further trading, nothing has changed.

The investigation findings, as we know, are potentially being used as evidence in the Yonemura case, which is adjourned until January. So there will be no public findings from the investigation released, until then.


So given the consistent standpoint from Woodford about awaiting the investigation findings, I take that at face value. As I do his reiterated statements about continuing to believe in the long-term potential of DCVax.